|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM266977162 |
| 003 |
DE-627 |
| 005 |
20231224215701.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1111/vcp.12429
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0889.xml
|
| 035 |
|
|
|a (DE-627)NLM266977162
|
| 035 |
|
|
|a (NLM)27935623
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Poitout-Belissent, Florence
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Reducing blood volume requirements for clinical pathology testing in toxicologic studies-points to consider
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 09.08.2017
|
| 500 |
|
|
|a Date Revised 09.08.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a © 2016 American Society for Veterinary Clinical Pathology.
|
| 520 |
|
|
|a In preclinical safety assessment, blood volume requirements for various endpoints pose a major challenge. The goal of this working group was to review current practices for clinical pathology (CP) testing in preclinical toxicologic studies, and to discuss advantages and disadvantages of methods for reducing blood volume requirements. An industry-wide survey was conducted to gather information on CP instrumentation and blood collection practices for hematology, clinical biochemistry, and coagulation evaluation in laboratory animals involved in preclinical studies. Based on the survey results and collective experience of the authors, the working group proposes the following "points to consider" for CP testing: (1) For most commercial analyzers, 0.5 mL and 0.8 mL of whole blood are sufficient for hematology and biochemistry evaluation, respectively. (2) Small analyzers with low volume requirements and low throughput have limited utility in preclinical studies. (3) Sample pooling or dilution is inappropriate for many CP methods. (4) Appropriate collection sites should be determined based on blood volume requirements and technical expertise. (5) Microsampling does not provide sufficient volume given current analyzer and quality assurance requirements. (6) Study design considerations include: the use of older/larger animals (rodents), collection of CP samples before toxicokinetic samples, use of separate subsets of mice for hematology and clinical biochemistry testing, use of a priority list for clinical biochemistry, and when possible, eliminating coagulation testing
|
| 650 |
|
4 |
|a Consensus Development Conference
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Industry survey
|
| 650 |
|
4 |
|a instrumentation
|
| 650 |
|
4 |
|a microsampling
|
| 650 |
|
4 |
|a nonhuman primates
|
| 650 |
|
4 |
|a rodents
|
| 650 |
|
4 |
|a sample dilution
|
| 700 |
1 |
|
|a Aulbach, Adam
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Tripathi, Niraj
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Ramaiah, Lila
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Veterinary clinical pathology
|d 1975
|g 45(2016), 4 vom: 01. Dez., Seite 534-551
|w (DE-627)NLM098159984
|x 1939-165X
|7 nnns
|
| 773 |
1 |
8 |
|g volume:45
|g year:2016
|g number:4
|g day:01
|g month:12
|g pages:534-551
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1111/vcp.12429
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 45
|j 2016
|e 4
|b 01
|c 12
|h 534-551
|